CN1679601A - Use of lotus flavone in triglyceride for reducing hyperlipemia - Google Patents
Use of lotus flavone in triglyceride for reducing hyperlipemia Download PDFInfo
- Publication number
- CN1679601A CN1679601A CN 200510018257 CN200510018257A CN1679601A CN 1679601 A CN1679601 A CN 1679601A CN 200510018257 CN200510018257 CN 200510018257 CN 200510018257 A CN200510018257 A CN 200510018257A CN 1679601 A CN1679601 A CN 1679601A
- Authority
- CN
- China
- Prior art keywords
- triglyceride
- group
- lotus flavone
- lotus
- flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of nelumboflavone in preparing the medicines for preventing and treating hyperlipemia, especially decreasing the triglyceride of hyperlipemia patient is disclosed. Its advantages are high curative effect, and no toxic by-effect.
Description
Technical field the present invention relates to lotus flavone reduces its triglyceride in hyperlipemia application.
The change of Background Art As people ' growth in the living standard and dietary structure, higher fatty acid and a large amount of absorptions high protein foods make hyperlipidemia present the trend that increases substantially in China.And hyperlipidemia is a heart disease, fatty liver, the major incentive of diseases such as cerebral thrombosis.Find have in the hyperlipemic patients to belong to simple property triglyceride greatly and increase or mainly show as triglyceride and increase by a large amount of investigations, this point is outstanding especially in China.The rising of clinical proof triglyceride level and atherosclerotic formation and coronary heart disease substantial connection arranged.Studies show that of coronarography and serum levels of triglyceride level has among the patient of obvious coronary stricture, and what triglyceride increased accounts for more than 1/3; The order of severity of coronary artery pathological changes has substantial connection with the height of serum levels of triglyceride content.Simultaneously, triglyceride content increases, and also can cause blood viscosity to increase, and the blood clotting tendency strengthens, and easily promotes thrombosis and atherosclerotic formation.This shows that triglyceride increases can cause very big threat to health, but as only, use triglyceride comprehensive blood lipid-lowering medicine (be often referred to can triglyceride reducing can cholesterol reducing medicine) again and not exclusively suitable because increasing, because do like this except the patient is born the side effect that blood lipid-lowering medicine brings health, also will make the patient bear the risk that normal cholesterol is lowered in the body.
Folium Nelumbinis (Nemlumbo lotus) property is flat nontoxic, gas delicate fragrance, and mildly bitter flavor is puckery, goes into warps such as liver, gallbladder, spleen, stomach, the heart, lung, large intestine, has the removing summer-heat pathogenic summer-heat, gently declares expelling pathogenic factors from the exterior, ascending the clear and descending the turbid, the appetizing of being amusing, the effects such as dissipating blood stasis, lowering blood-fat and reducing weight of stopping blooding.Medical value for the exploitation Folium Nelumbinis, the applicant once proposed " a kind of extracting method of lotus flavone " patent application (number of patent application 021390487) after deliberation, its technology follows these steps to carry out: with dry Folium Nelumbinis washing, air-dry, pulverizing, get Lotus Leaf, it is put into the percolation device, with ethanol percolate extraction concentrating under reduced pressure again, make meticulous lotus flavone powder through macroporous adsorbent resin separation, organic solvent purification, post processing.The applicant has carried out its purposes research with the lotus flavone that extracts.
Summary of the invention the objective of the invention is to aim to provide a kind of purposes of lotus flavone based on above-mentioned background and research basis, that is the effect of triglyceride reducing in hyperlipidemia.
The implementation of the object of the invention is that the application of the triglyceride of lotus flavone in reducing hyperlipidemia is that lotus flavone is used from the triglyceride that reduces in the hyperlipidemia separately or with other corresponding plants, animal product or adjuvant one.
When lotus flavone used with other corresponding plants, animal product or adjuvant, lotus flavone content was 1-99%, and satisfied the human dosage of 0.1g/kg-0.9g/kg, and animal dosage converts according to people's dose,equivalent.
The present invention proposes the application of the triglyceride of lotus flavone in reducing hyperlipemia, the raw material of used lotus flavone is a Folium Nelumbinis, and it is very extensive to originate, and the preparation process environmental pollution is little.Lotus flavone is used for reducing the triglyceride of hyperlipidemia, does not have toxicity and other side effect, uses as safe as a housely, and the average range of decrease of triglyceride is greater than 15%.Lotus flavone also can be used for prevention and treatment hyperlipidemia.
The specific embodiment the invention provides the application of the triglyceride of lotus flavone in reducing hyperlipemia.In order to prove that lotus flavone is used for reducing the effect of the triglyceride of hyperlipidemia, the applicant has carried out following test, and the result is as follows:
1. The acute toxicity tests
Because the low toxicity of Folium Nelumbinis own carries out the median lethal dose(LD 50) test and has any problem, so select mtd test.Test method: get SPF level KM mice, 20, male and female half and half.With the lotus flavone saturated solution of concentration 10%, irritate stomach with the dosage of 0.2ml/10g, distinguished again once later in 6 hours and 12 hours with the 0.1ml/10g dosed administration.This moment, total dosage of mice was 400g crude drug/kg.Conversion is 44g crude drug/kg for human dosage.Result of the test: raised continuously 14 days, all mices all survive, and dissect and find that not tissue has tangible pathological changes phenomenon.
Result of the test explanation lotus flavone is under 400g crude drug/kg condition at the dosage of mice, does not have toxicity, uses as safe as a house.
2, results of pharmacodynamic test
Pharmacodynamics test divides and carries out for three times, is that lotus flavone is individually dosed for the first time, determines whether lotus flavone has the effect of triglyceride reducing; Test is for the second time verified its compound recipe effect for lotus flavone and Radix Oenotherae erythrosepalae oil and chitin compound recipe; Test for the third time is for making the preparation of lotus flavone crude drug and its adding adjuvant lipid-lowering effect relatively, and the checking adjuvant is to the influence of effect for reducing fat.
2.1 single lotus flavone pharmacodynamics test:
Get 48 of male SPF level Wistar rats, the adequacy test environment is divided into 6 groups according to triglyceride level after one week, 8 every group.One group is normal group (giving normal feedstuff), one group is the hyperlipidemia model matched group in other 5 groups, one group is zhibituo contrast medicine group, and its excess-three group is respectively the high, medium and low dosage group of lotus flavone (1.4g flavone/kg, 0.7g flavone/kg, 0.35 flavone/kg), all give high lipid food.Give in 5 groups of rat fat levels of high lipid food TG (triglyceride) and TC (cholesterol) content after 2 weeks and all raise, surpass normal group 50%, the modeling success.At this moment, each group is gastric infusion respectively, and normal group and hyperlipidemia model group are irritated stomach with normal saline, 3 weeks of successive administration.It is jejunitas to put to death preceding 18 hours of rat, and the rat jugular vein is got blood, detects triglyceride level behind the separation of serum.
Result of the test: under the situation of hyperlipidemia feedstuff that continues to feed, lotus flavone still has the effect of good reduction serum TG.Specific as follows: normal group average T G is 1.55mmol/L, hyperlipidemia group average out to 2.57mmol/L, positive drug group 2.03mmol/L, lotus flavone high dose group 1.81mmol/L, middle dosage group 1.21mmol/L, low dose group 1.51mmol/L.
The triglyceride level of three administration groups of lotus flavone recovers normal level substantially after 3 weeks of administration.Evidence, lotus flavone have the effect of fabulous triglyceride reducing, and the effect of lotus flavone triglyceride reducing is definite.
2.2 single lotus flavone and its mixture pharmacodynamics comparative test
Get 40 of male SPF level Wistar rats, the adequacy test environment is divided into 5 groups according to triglyceride level after one week, 8 every group.One group is normal group (giving normal feedstuff), and one group is the hyperlipidemia model matched group in other 4 groups, one group be the lotus flavone group (0.7g flavone/kg), one group is lotus flavone and Radix Oenotherae erythrosepalae oil compound recipe group (abbreviate lotus moon mixture as, down with), dosage 8ml/kg; One group is lotus flavone and chitin compound recipe group (abbreviating lotus first mixture as, down together), and dosage 1.0g/kg all gives high lipid food.Give in 4 groups of rat fat levels of high lipid food TG and TC content after 2 weeks and all raise, surpass normal group 50%, the modeling success.At this moment, each group is gastric infusion respectively, and normal group and hyperlipidemia model group are irritated stomach with normal saline, 3 weeks of successive administration.It is jejunitas to put to death preceding 18 hours of rat, and the rat jugular vein is got blood, detects triglyceride level behind the separation of serum.
Result of the test is as follows: normal group average T G be 1.51mmol/L, hyperlipidemia group be 2.3mmol/L, lotus flavone dosage group be 1.21mmol/L, the lotus moon mixture group be that 1.1mmol/L, lotus first mixture group are 1.25mmol/L.The proof lotus flavone and the lotus moon mixture, lotus first mixture all have the effect of good reduction serum TG (triglyceride), TG still can recover normal level.
Above result shows that also compound preparation has the effect of good reduction serum TG, and the plant of interpolation or animal product are not obvious to the potentiation of lotus flavone, this shows that the effect of lotus flavone reduction serum TG in the compound preparation is definite and stable.
2.3 lotus flavone and adjuvant share the influence test to the triglyceride reducing effect
Get 32 of male SPF level Wistar rats, the adequacy test environment is divided into 4 groups according to triglyceride level after one week, 8 every group.One group is normal group (giving normal feedstuff), and one group is the hyperlipidemia model matched group in other 3 groups, and one group is lotus flavone crude drug group, and one group is lotus flavone tablet group, all gives high lipid food.Give in 3 groups of rat fat levels of high lipid food TG and TC content after 2 weeks and all raise, surpass normal group 50%, the modeling success.At this moment, each group is gastric infusion respectively, and normal group and hyperlipidemia model group are irritated stomach with normal saline, 3 weeks of successive administration.It is jejunitas to put to death preceding 18 hours of rat, and the rat jugular vein is got blood, detects triglyceride level behind the separation of serum.Result of the test is as follows: normal group average T G is that 1.57mmol/L, hyperlipidemia group are that 2.7mmol/L, lotus flavone crude drug group are 1.30mmol/L, and lotus flavone tablet group is 1.32mmol/L.Proof is under the situation of hyperlipidemia feedstuff that continues to feed, and lotus flavone crude drug group and lotus flavone tablet group be the triglyceride reducing level significantly, does not have significant difference between two administration groups.Illustrate whether add adjuvant, do not influence the effect of lotus flavone triglyceride reducing.
3, the applicant entrusts Hubei Province's prevention and treatment of chronic diseases institute to carry out the preliminary test of total flavones reduction hyperlipemia serum levels of triglyceride
Hubei Province prevention and treatment of chronic diseases institute has carried out the test that lotus flavone reduces its triglyceride to the hyperlipidemia volunteer.Select volunteer's condition to be: (1) does not obey any fat regulation medicine at least through general diet control in 4 weeks, respectively survey blood fat 2 weeks 1 time at interval, and 2 inspections are serum TG＞1.71mmol/L person on an empty stomach; (2) 53 ± 9 years old age; (3) patient's voluntary cooperation; (4) get rid of one of following situation: nearly 6 months troubles myocardial infarctions, cerebrovascular accident, the Secondary cases hyperlipidemia that experience major operation or severe trauma, medicine (thiazide, receptor blocking agent, hormones etc.) cause, thyroid illness, diabetes, hepatorenal disease, malignant tumor etc.5 altogether of volunteers, male 3 examples, women 2 examples; 53 ± 9 years old age.The experimenter keeps original dietary habit constant, and life style is relatively stable, gives the lotus flavone capsule, and every day 2 times, each 2, every capsules contains lotus flavone 300mg, takes continuously 30 days.Measure treatment front and back empty stomach in early morning vein serum TG level.Result of the test: average T G level is 2.5mmol/L before the administration, is reduced to 2.1mmol/L after the administration, and the level of triglyceride all has decline in various degree in 5 volunteer's blood, and the average range of decrease is greater than 15%.
More than all evidences: lotus flavone is to use separately or compound recipe uses and all has good triglyceride reducing effect, preliminary identification to the reduction effect of human serum triglyceride.
Claims (2)
1, the application of the triglyceride of lotus flavone in reducing hyperlipemia is characterized in that lotus flavone is used from the hyperlipemia separately or with other corresponding plants, animal product or adjuvant one, reduces its triglyceride.
2, the application of the triglyceride of lotus flavone according to claim 1 in reducing hyperlipemia, when it is characterized in that lotus flavone uses with other corresponding plants, animal product or adjuvant, lotus flavone content is 1-99%, and satisfy the human dosage of 0.1g/kg-0.9g/kg, animal dosage converts according to people's dose,equivalent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510018257 CN1679601A (en) | 2005-02-05 | 2005-02-05 | Use of lotus flavone in triglyceride for reducing hyperlipemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510018257 CN1679601A (en) | 2005-02-05 | 2005-02-05 | Use of lotus flavone in triglyceride for reducing hyperlipemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679601A true CN1679601A (en) | 2005-10-12 |
Family
ID=35066609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510018257 Pending CN1679601A (en) | 2005-02-05 | 2005-02-05 | Use of lotus flavone in triglyceride for reducing hyperlipemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679601A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687497A (en) * | 2016-02-19 | 2016-06-22 | 福建农林大学 | Plumula nelumbinis flavonoid compound containing composition and application thereof to blood lipid reduction |
-
2005
- 2005-02-05 CN CN 200510018257 patent/CN1679601A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687497A (en) * | 2016-02-19 | 2016-06-22 | 福建农林大学 | Plumula nelumbinis flavonoid compound containing composition and application thereof to blood lipid reduction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100999616A (en) | Preparation process of squid ink black pigment and application thereof | |
| CN102961733A (en) | Application of seaweed polypeptide in preparing health-care product for reducing blood fat and blood sugar as well as beverage containing polypeptide for reducing blood fat and blood sugar | |
| CN103637185B (en) | Nervonic acid composition | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN111166820B (en) | Traditional Chinese medicine composition containing fingered citron, preparation and application | |
| CN101703497B (en) | Application of Chlorogenic acid in preparing drug having protection and restoration functions on spleen hematopoietic stem cell injuries | |
| CN115444893B (en) | Uric acid reducing active substance composition and application thereof | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN1679601A (en) | Use of lotus flavone in triglyceride for reducing hyperlipemia | |
| CN101212963B (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN1389475A (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN111514244A (en) | Extraction method and application of dendrobium officinale extract | |
| CN1231224C (en) | Sealwort polysaccharide konjaku glucomannan capsule | |
| JP5410152B2 (en) | Anemia prevention composition | |
| US20030225001A1 (en) | Preparation of an auricularia auricula polysaccharide and its use in mammals | |
| CN103768294A (en) | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes | |
| CN100434085C (en) | Process for removing toxic component from oleum fructus bruceae | |
| CN101474367B (en) | Pharmaceutical composition for reducing blood sugar | |
| CN105902601B (en) | Tamarind shell extract is preparing the application in blood lipid-lowering medicine | |
| CN1135856A (en) | Health-care food for diabetes and its production | |
| CN1879702A (en) | A medicine for preventing and treating diabetes, preparation method and application thereof | |
| CN107412283A (en) | A kind of three high drop composition containing Agricus blazei extract and preparation method thereof | |
| JP2006117566A (en) | Saccharometabolism-ameliorating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |